Who Should Receive an Allogeneic Transplant in First Complete Remission?
Who Should Receive an Allogeneic Transplant in First Complete Remission?
Clin Lymphoma Myeloma Leuk. 2020 Sep;20 Suppl 1:S48-S51
Authors: Ribera JM, Genescà E, Ribera J
Abstract
The decision to incorporate allogeneic hematopoietic stem cell transplant (allo-HSCT) into front-line therapy in adult acute lymphoblastic leukemia (ALL) should be primarily guided by measurable residual disease (MRD) status and the ALL regimen utilized. While there is no doubt that allo-HSCT benefits patients with poor MRD response after induction or consolidation, the indication of allo-HSCT in cases of good MRD clearance is not clear. As targeted immunotherapies result in high MRD-negative CR rates, early incorporation of these therapies may also prove valuable in reducing the need for HCT in the front-line setting. This review discusses the data and controversies related to allo-HSCT in the front-line therapy of Philadelphia chromosome-negative and -positive ALL.
PMID: 32862866 [PubMed - in process]
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Ribera JM, Genescà E, Ribera J Tags: Clin Lymphoma Myeloma Leuk Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer & Oncology | Immunotherapy | Leukemia | Lymphoma | Myeloma | Stem Cell Therapy | Stem Cells | Transplants